WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced that Dr. Charles Morris has joined the company as chief medical officer as it advances its oncology pipeline toward clinical development.
Morris will oversee clinical strategy and development as Prelude prepares to move two lead programs targeting myeloproliferative neoplasms and ER-positive breast cancer into clinical trials expected to begin in 2026.
He brings more than 30 years of experience in oncology drug development, including leadership roles at biotechnology and pharmaceutical companies where he managed multiple drug approvals.
Most recently, Morris served as chief medical officer at Lava Therapeutics. He previously held chief medical officer roles at Celyad Oncology and Radius Health, and contributed to the development of treatments including ONSERDU for breast cancer and ELAHERE for ovarian cancer.
Earlier in his career, he worked at AstraZeneca, where he served as global medical lead for Faslodex, supporting its approval for advanced breast cancer.
“With the strong science and thorough understanding of the unmet needs that have driven these programs, I see a real opportunity to make an important difference for patients,” Morris said.
Prelude Therapeutics is a clinical-stage company focused on developing targeted cancer therapies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.